Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

1,617 public trials 340 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • City of Hope National Medical Center /ID# 273338 Duarte, California, United States
  • Valkyrie Clinical Trials /ID# 269935 Los Angeles, California, United States
  • Desert Regional Medical Center /ID# 272437 Palm Springs, California, United States
  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823 Golden, Colorado, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, Not Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660

Conditions
Burkitt Lymphoma, DNA Virus Infections, Disease Attributes, +19 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Diego Health (UCSD) La Jolla, California, United States
  • University of California Davis (UC Davis) Sacramento, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

NCT05798156

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Uniklinik Innsbruck Innsbruck, Austria
  • Kepler Universitätsklinikum Linz, Austria
  • Ordensklinikum Linz - Barmherzige Schwestern Linz, Austria
  • Ordensklinikum Linz - Elisabethinen Linz, Austria
View all 28 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Wien Vienna, Austria
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy
View Trial Details
Active, Not Recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • MorphoSys Research Site Daphne, Alabama, United States
  • MorphoSys Research Site Anaheim, California, United States
  • MorphoSys Research Site Clovis, California, United States
  • MorphoSys Research Site Fullerton, California, United States
View all 307 locations
View Trial Details

Related conditions